Publicaciones (321) Publicaciones en las que ha participado algún/a investigador/a

2018

  1. CD34 + Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome 

    Biology of Blood and Marrow Transplantation, Vol. 24, Núm. 5, pp. 964-972

  2. Characterization of CD34 + hematopoietic cells in systemic mastocytosis: Potential role in disease dissemination

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 6, pp. 1294-1304

  3. Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia

    Haematologica, Vol. 103, Núm. 6, pp. 1029-1037

  4. A Perspective on Proteomics of Infectious Diseases

    Proteomics - Clinical Applications, Vol. 12, Núm. 4

  5. A body shape index and vascular structure and function in Spanish adults (MARK study) A cross-sectional study

    Medicine (United States), Vol. 97, Núm. 47

  6. A community approach to mortality prediction in sepsis via gene expression analysis

    Nature Communications, Vol. 9, Núm. 1

  7. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America

    Journal of Medical Economics, Vol. 21, Núm. 5, pp. 525-536

  8. A cross-sectional study of the impact of educational information on topical photoprotection habits in medical students

    Semergen, Vol. 44, Núm. 6, pp. 420-429

  9. A multicentre randomized pilot trial on the effectiveness of different levels of cooling in comatose survivors of out-of-hospital cardiac arrest: the FROST-I trial

    Intensive Care Medicine, Vol. 44, Núm. 11, pp. 1807-1815

  10. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis

    Blood Advances, Vol. 2, Núm. 18, pp. 2400-2411

  11. A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease

    Blood Advances, Vol. 2, Núm. 21, pp. 2959-2963

  12. A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: Biological and clinical utility

    Haematologica, Vol. 103, Núm. 5, pp. 880-889

  13. A personalized intervention to prevent depression in primary care: Cost-effectiveness study nested into a clustered randomized trial

    BMC Medicine, Vol. 16, Núm. 1

  14. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study

    Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704

  15. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalanprednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

    Haematologica, Vol. 103, Núm. 9, pp. 1518-1526

  16. A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia

    Annals of Hematology, Vol. 97, Núm. 5, pp. 763-772

  17. A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma

    Critical Reviews in Oncology/Hematology, Vol. 121, pp. 74-89

  18. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome

    Kidney International, Vol. 93, Núm. 2, pp. 450-459

  19. A safety profile of medications used to treat Waldenström’s macroglobulinemia

    Expert Opinion on Drug Safety, Vol. 17, Núm. 6, pp. 609-621

  20. A survey of perceptions, attitudes, knowledge and practices of medical oncologists about cancer pain management in Spain

    Clinical and Translational Oncology, Vol. 20, Núm. 8, pp. 1061-1071